CompletedNCT00839852
What is this study about?Researchers studied Cariprazine to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Costa MesaSchizophreniaMedication studyAges 18–61
- Countries
- United States, India, Malaysia, + 2 others
- Sponsor
- Forest Laboratories
CompletedNCT01412060
Official study titleA Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–60
- Countries
- United States, India, Romania, + 2 others
- Sponsor
- Forest Laboratories
CompletedNCT06340958
What is this study about?This study evaluated the safety and effectiveness of CLE-100 for people with depression.
This study has finished and is no longer accepting participants.
Multiple locations, including La JollaDepressionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Clexio Biosciences Ltd.
CompletedNCT04294719
Official study titleA Study of Cognitive Adaptation Training in Inpatient Forensic Environments
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaObservational studyAges 18+
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT00564954
About this title
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
Read the official source — NCT00564954Official study titleA Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockADHDMedication studyAges 6–12
- Countries
- United States
- Sponsor
- Novartis Pharmaceuticals
CompletedNCT01729026
Official study titleA Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder
This study has finished and is no longer accepting participants.
In San AntonioPTSDInterventional studyAges 18+
- Countries
- United States
- Sponsor
- VA Office of Research and Development (Government agency)
CompletedNCT00796432
Official study titleOpen-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 20–45
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT05012709
Official study titleDeveloping a Healthy Care Environment in Psychiatry: A Study of Dose-response Relationship and the Evidence Based Multisensory Stimulation Intervention
This study has finished and is no longer accepting participants.
In TainanAnxiety, SchizophreniaBehavioural study
- Countries
- Taiwan
- Sponsor
- Jianan Psychiatric Center, Ministry of Health and Welfare
CompletedNCT00086320
About this title
A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.
Read the official source — NCT00086320Official study titleA Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.